229 related articles for article (PubMed ID: 20332301)
1. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.
Beatty PL; Narayanan S; Gariépy J; Ranganathan S; Finn OJ
Cancer Prev Res (Phila); 2010 Apr; 3(4):438-46. PubMed ID: 20332301
[TBL] [Abstract][Full Text] [Related]
2. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer.
Beatty PL; Plevy SE; Sepulveda AR; Finn OJ
J Immunol; 2007 Jul; 179(2):735-9. PubMed ID: 17617560
[TBL] [Abstract][Full Text] [Related]
3. Experimental vaccine against inflammatory bowel disease and colon cancer.
Immunotherapy; 2010 May; 2(3):299. PubMed ID: 20658752
[No Abstract] [Full Text] [Related]
4. Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.
Kadayakkara DK; Beatty PL; Turner MS; Janjic JM; Ahrens ET; Finn OJ
Pancreas; 2010 May; 39(4):510-5. PubMed ID: 20084048
[TBL] [Abstract][Full Text] [Related]
5. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
6. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of hematopoietic MUC1 during experimental colitis increases tumor-promoting myeloid-derived suppressor cells.
Poh TW; Madsen CS; Gorman JE; Marler RJ; Leighton JA; Cohen PA; Gendler SJ
Clin Cancer Res; 2013 Sep; 19(18):5039-52. PubMed ID: 23873692
[TBL] [Abstract][Full Text] [Related]
8. Prevention of colitis-associated colon cancer using a vaccine to target abnormal expression of the MUC1 tumor antigen.
Beatty P; Ranganathan S; Finn OJ
Oncoimmunology; 2012 May; 1(3):263-270. PubMed ID: 22737601
[TBL] [Abstract][Full Text] [Related]
9. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
10. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
[TBL] [Abstract][Full Text] [Related]
11. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
Ryan SO; Turner MS; Gariépy J; Finn OJ
Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
[TBL] [Abstract][Full Text] [Related]
12. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
13. The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy.
Guo M; You C; Dong W; Luo B; Wu Y; Chen Y; Li J; Pan M; Li M; Zhao F; Dou J
Biomed Pharmacother; 2020 Dec; 132():110804. PubMed ID: 33017767
[TBL] [Abstract][Full Text] [Related]
14. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease.
Furr AE; Ranganathan S; Finn OJ
Pediatr Dev Pathol; 2010; 13(1):24-31. PubMed ID: 19025220
[TBL] [Abstract][Full Text] [Related]
16. Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas.
Beatty PL; Finn OJ
Ann N Y Acad Sci; 2013 May; 1284():52-6. PubMed ID: 23651193
[TBL] [Abstract][Full Text] [Related]
17. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
[TBL] [Abstract][Full Text] [Related]
18. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
19. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
20. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
